Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach

Phoebe T. M. Cheng, Diego Villa, R. Petter Tonseth, David W. Scott, Alina S. Gerrie, Ciara L. Freeman, Tom Pickles, Andrea C. Lo, Pedro Farinha, Jeffrey W. Craig, Graham W. Slack, Randy D. Gascoyne, François Bénard, Don Wilson, Brian Skinnider, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Blood Adv (2021) 5 (18): 3647–3655.

https://doi.org/10.1182/bloodadvances.2021004375

Published: 2021

Journal Articles

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Blood Adv (2021) 5 (18): 3623–3632.

https://doi.org/10.1182/bloodadvances.2021004645

Published: 2021

Includes: Supplemental data

Journal Articles

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Hasmukh Jain, Manju Sengar, Vasu Babu Goli, Jayashree Thorat, Prashant Tembhare, Dhanlaxmi Shetty, V. N. Avinash Bonda, Lingaraj Nayak, P. G. Subramanian, Bhausaheb Bagal, Nikhil Patkar, Neha Sharma, Himanshi Gupta, Sumeet Gujral

Blood Adv (2021) 5 (17): 3436–3444.

https://doi.org/10.1182/bloodadvances.2020003368

Published: 2021

Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Blood Adv (2021) 5 (15): 2935–2944.

https://doi.org/10.1182/bloodadvances.2020003985

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Blood Adv (2021) 5 (13): 2775–2787.

https://doi.org/10.1182/bloodadvances.2021004233

Published: 2021

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Blood Adv (2021) 5 (13): 2707–2716.

https://doi.org/10.1182/bloodadvances.2020004155

Published: 2021

Includes: Supplemental data

Journal Articles

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Parastoo B. Dahi, Jasme Lee, Sean M. Devlin, Josel Ruiz, Molly Maloy, Carlos Rondon-Clavo, Erica Petrlik, Roni Tamari, Gunjan Shah, Michael Scordo, Matthew J. Matasar, Paul A. Hamlin, Esperanza Papadopoulos, Ann A. Jakubowski, Miguel-Angel Perales, Craig H. Moskowitz, Craig S. Sauter, Sergio A. Giralt

Blood Adv (2021) 5 (12): 2608–2618.

https://doi.org/10.1182/bloodadvances.2020004167

Published: 2021

Includes: Supplemental data

Journal Articles

Qi S-N, Yang Y, Song Y-Q, et al. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020;4(13):3141-3153.

Blood Adv (2021) 5 (12): 2576.

https://doi.org/10.1182/bloodadvances.2021005072

Published: 2021

Journal Articles

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Cheng-Hong Tsai, Jih-Luh Tang, Feng-Ming Tien, Yuan-Yeh Kuo, Dung-Chi Wu, Chien-Chin Lin, Mei-Hsuan Tseng, Yen-Ling Peng, Mei-Fang Hou, Yi-Kuang Chuang, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, Liang-In Lin, Wen-Chien Chou, Chien-Yu Chen, Hsin-An Hou, Hwei-Fang Tien

Blood Adv (2021) 5 (10): 2456–2466.

https://doi.org/10.1182/bloodadvances.2020003738

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond

Blood Adv (2021) 5 (9): 2438–2446.

https://doi.org/10.1182/bloodadvances.2020003895

Published: 2021

Includes: Supplemental data

Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek

Blood Adv (2021) 5 (8): 2156–2164.

https://doi.org/10.1182/bloodadvances.2020003934

Published: 2021

Includes: Supplemental data

Journal Articles

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

Sandheeah Ramdeny, Asima Chaudhary, Austen Worth, Sara Ghorashian, Mary Slatter, Su Han Lum, Ajay Vora

Blood Adv (2021) 5 (8): 2153–2155.

https://doi.org/10.1182/bloodadvances.2021004284

Published: 2021

Journal Articles

Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial

Etan Orgel, Celia Framson, Rubi Buxton, Jiyoon Kim, Gang Li, Jonathan Tucci, David R. Freyer, Weili Sun, Matthew J. Oberley, Christina Dieli-Conwright, Steven D. Mittelman

Blood Adv (2021) 5 (7): 1853–1861.

https://doi.org/10.1182/bloodadvances.2020004018

Published: 2021

Includes: Supplemental data

Journal Articles

Involved-site radiotherapy for Helicobacter pylori –independent gastric MALT lymphoma: 26 years of experience with 178 patients

Joachim Yahalom, Amy J. Xu, Ariela Noy, Stephanie Lobaugh, Monica Chelius, Karen Chau, Carol Portlock, Carla Hajj, Brandon S. Imber, David J. Straus, Craig H. Moskowitz, Morton Coleman, Andrew D. Zelenetz, Zhigang Zhang, Ahmet Dogan

Blood Adv (2021) 5 (7): 1830–1836.

https://doi.org/10.1182/bloodadvances.2020003992

Published: 2021

Journal Articles

Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study

Blood Adv (2021) 5 (7): 1837–1847.

https://doi.org/10.1182/bloodadvances.2020003453

Published: 2021

Includes: Supplemental data

Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet

Blood Adv (2021) 5 (6): 1719–1728.

https://doi.org/10.1182/bloodadvances.2020003510

Published: 2021

Includes: Supplemental data

Journal Articles

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Blood Adv (2021) 5 (6): 1648–1659.

https://doi.org/10.1182/bloodadvances.2020003556

Published: 2021

Includes: Supplemental data

Journal Articles

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K. Genutis, Marius Bill, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Albert de la Chapelle, Clara D. Bloomfield

Blood Adv (2021) 5 (5): 1474–1482.

https://doi.org/10.1182/bloodadvances.2020003727

Published: 2021

Includes: Supplemental data

Journal Articles

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study

Johanne Rozema, Mels Hoogendoorn, Robby Kibbelaar, Eva van den Berg, Nic Veeger, Eric van Roon

Blood Adv (2021) 5 (5): 1344–1351.

https://doi.org/10.1182/bloodadvances.2020003381

Published: 2021

Includes: Supplemental data

Journal Articles

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri A. Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjorn T. Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J. M. Valk, Catharina H. M. J. van Elssen, Markus G. Manz, Yngvar Floisand, Gert J. Ossenkoppele

Blood Adv (2021) 5 (4): 1110–1121.

https://doi.org/10.1182/bloodadvances.2020003855

Published: 2021

Includes: Supplemental data

NARROW

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Qi S-N, Yang Y, Song Y-Q, et al. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020;4(13):3141-3153.

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial

Involved-site radiotherapy for Helicobacter pylori –independent gastric MALT lymphoma: 26 years of experience with 178 patients

Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only